DST

Drug Susceptibility Testing (DST)

Laboratory determination of the effectiveness of specific antimicrobial agents against bacterial and fungal pathogens.

Method
Broth dilution, agar dilution, disk diffusion, E-test, molecular methods
Turnaround
Data to be updated
Specimen
Data to be updated
Sample volume
Data to be updated

Why This Test Matters

DST is crucial in guiding appropriate treatment and combating antibiotic resistance. It identifies effective treatment by determining which drugs a pathogen is sensitive or resistant to; it monitors resistance trends for public-health surveillance; and it underpins quality control of antimicrobial agents and testing procedures in clinical laboratories.

Clinical Background

The Diagnostic Challenge

Current Diagnostic Methods

Broth dilution exposes the pathogen to varying antimicrobial concentrations in liquid medium to determine the minimum inhibitory concentration (MIC). Agar dilution performs the same on solid media. Disk diffusion (Kirby–Bauer) measures the zone of inhibition around antibiotic disks. The E-test uses a gradient strip — the point where growth intersects the strip indicates the MIC. Molecular methods such as PCR detect genetic markers associated with resistance.

How the ID Labs Test Helps

ID Labs performs DST across these established methods, ensuring infections are treated with the most effective and appropriate antimicrobial agents.

Test Methodology

MethodologyBroth dilution, agar dilution, disk diffusion, E-test, molecular methods
TechnologyPhenotypic + molecular DST
InstrumentData to be updated
DetectionData to be updated

Specimen Information

Specimen requirements: data to be updated. Please contact ID Labs.

Specimen Container

Container information: data to be updated.

Targets / Analytes / Organisms

Validated target list: data to be updated. Please contact ID Labs for the current configuration.

Technical Performance

CharacteristicValueSource
Analytical / clinical performancePerformance characteristics: please contact ID Labs — data to be updated.ID Labs Validated Performance

Clinical Utilization

Any significant isolate where therapy decisions depend on susceptibility; surveillance of local resistance patterns; confirmation of molecular resistance results.

Advantages

  • Guides individualised, effective therapy
  • Tracks resistance emergence and spread
  • Ensures quality control of testing

Limitations

  • Requires viable isolates for phenotypic methods
  • Breakpoint values are defined by CLSI/EUCAST and are periodically updated — current standards are always applied
  • Molecular methods detect markers, not the full resistance phenotype

Publications & Scientific Evidence

Xpert MTB/RIF and Xpert Ultra for pulmonary TB and rifampicin resistance: Cochrane review

Cochrane Database of Systematic Reviews · 2021

Meta-analysisExternal link only

Curated peer-reviewed / authoritative reference. Open the source link for the full text.

WHO Technical Manual for Drug-Susceptibility Testing of M. tuberculosis (BACTEC MGIT 960)

World Health Organization · 2018

GuidelineExternal link only

Curated peer-reviewed / authoritative reference. Open the source link for the full text.

Related Tests & Technologies

Discuss this test with our scientific team

Panel configuration, specimen logistics and turnaround details on request.

Enquire now

Information on this page is educational and does not replace professional clinical judgment. Performance values are labelled by source (ID Labs Specification / ID Labs Validated Performance / Manufacturer Specification / Published Scientific Evidence). Molecular results must be correlated clinically and, where appropriate, confirmed by culture and phenotypic susceptibility testing.